Myeloma MRD Flow Panel

Submitted by Anonymous (not verified) on
Code
FLG-MMRD-03BX
Panel
Active-Compendium
88184x1, 88185x11. Add 88188x1 for global
Clinical
Oncology,Pathology
Bone marrow aspirate: 3-4 mL EDTA preferred. Sodium heparin tube is acceptable. Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report.
NY Clients: Please provide Date and Time of Collection.
Hematologic Diseases
Plasma cell myeloma
Flow Cytometry
Global
Flag Active
True
Orderable Test Description
Markers include VS38c, CD19, CD20, CD27, CD45, CD56, CD81, CD117, CD138, CD269(BCMA), cKappa, and cLambda(12 markers).
Orderable Turn Around Time
2 Days
Keywords
mrd
MM
MM MRD
Myeloma
Multiple Myeloma
Myeloma MRD
Minimal Residual Disease
Meta Description
The Myeloma MRD Flow Panel evaluates for the presence of minimal residual disease in patients with previously diagnosed/treated multiple myeloma. Markers include VS38c, CD19, CD20, CD27, CD45, CD56, CD81, CD117, CD138, CD269(BCMA), cKappa, and cLambda(12 markers). The LOD is 0.01%.
Extra Note

Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report. NYS clients please provide date and time of Collection.

Orderable Biomarkers
CD20
CD81
CD117
VS38c
CD27
CD56
CD19
CD269 (BCMA)
cKappa
cLambda
CD138
CD45
NY Approved
True
Orderable Biomarkers JSON
{"Flow Cytometry": {"Markers": ["CD20", "CD81", "CD117", "VS38c", "CD27", "CD56", "CD19", "CD269 (BCMA)", "cKappa", "cLambda", "CD138", "CD45"]}}
Keywords string
MRD, MM, MM MRD, Myeloma, Multiple Myeloma, Myeloma MRD, Minimal Residual Disease Myeloma MRD Flow Panel
Title URL
myeloma-mrd-flow-panel